Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for that link! I hope we have other fat ladies in the wings, waiting to sing for us (LOL!!).
Thanks! Definitely looking forward to the update!
Here's the interesting information from Pluristem's "Top-Line Results" from P2 IC study:
(June 12, 2018)
Revascularization risk was reduced by 49% (Hazard ratio = 0.51) in the main efficacy group at week 65. Patients receiving 2 administrations of PLX-PAD cells originating from different placentas were “revasc-free” (no revascularization events) at week 65.
The result from the "main efficacy group" is very impressive, but it's the second group that is even more exciting: "no revascularization events) at week 65"
If that holds up (and we get some confirmation in the next few months), that would be stunning. Also note that the CLI study is using the same protocol as the second group.
Comments from participating investigators (from same announcement):
“We are highly encouraged by the results seen in the study. The option of treating peripheral artery diseases like IC and CLI through IM injections of PLX-PAD cells is promising, and an important outcome, demonstrating the potential ability to implement regenerative medicine advanced technologies in cardiovascular diseases. We look forward to the CLI pivotal study results that may demonstrate the ability of Pluristem’s cell therapy to improve patient outcomes and create economic benefits for the healthcare systems,” stated Dr. Manesh Patel, Chief of the Division of Cardiology at Duke University Health System, and the lead principle investigator (PI) for the U.S. Phase II IC study.
“These promising results demonstrate a clinically meaningful treatment effect. Finding a non-surgical medical solution for PAD, especially in patients who are unsuitable for revascularization, has proven to be one of the biggest medical challenges in recent years. These study results are highly encouraging and
suggest that PLX-PAD cells may be the answer for both PAD patients and physicians seeking effective medical solutions,” commented Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead PI for the European Phase II IC study.
boatnamed, I think you highlighted a very important part of the text
Very interesting, and, very relevant for Pluristem:
(from) European Commission’s Horizon 2020 research and innovation plan:
Alongside the Cell and Gene Therapy Catapult, the founding partners of the RESTORE consortium comprise world leaders across academia, clinical research and industry, including Charité Universitätsmedizin Berlin (Germany), INSERM – Institut National de la Santé et de la Recherche (France), University of Zurich (Switzerland), Miltenyi Biotec GmbH (Germany), TissUse GmbH (Germany), Pluristem Ltd (Israel), Fondazione Telethon (Italy), University Minho (Portugal) and Innovation Acta S.r.l. (Italy).
Clearly, Pluristem is part of the most important avant-garde in the most important new medical paradigm, i.e. harnessing the power of stem cells as therapeutic agents. Note that the article includes Pluristem in a very exclusive club: world leaders across academia, clinical research and industry
Thanks for the link Allo!
PS: I just noticed that the same paragraph was already excerpted by Allo in the next post, but I'll leave this anyway, I think it's very important to appreciate the arena Pluristem is playing in!
Thanks for the link (HereToFightScams), I enjoyed it!
BTW, my "sarcasm-phobia" is a direct result of reading raja's posts, I was quite healthy before I started following this board. I think we'll all feel better when the pps starts moving upward in a sustained way.
Monty Python is great!
A very cogent post!
Thanks for the link! How do these guys and gals at Pluristem find the bandwidth to do all this stuff. One more behind the scenes activity. I get the impression that they work real hard. Also that they're major players in the world of stem cell reseach, especially as it relates to some of Pluristem's target indications (muscle regeneration).
Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration
From 2017-10-01 to 2021-09-30, ongoing project
NMBP-15-2017 - Nanotechnologies for imaging cellular transplants and regenerative processes in vivo
Call for proposal:
...
Participants:
BAR ILAN UNIVERSITY Israel
PLURISTEM LTD Israel
EU contribution: EUR 487 500MATAM INDUSTRIAL PARK BLDG 20
31905 HAIFA
Israel
...
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ Germany
...
You're welcome! (EOM)
You need to look more carefully!! (Thunderbolt too!)
Conflict of interest statement
Dr. Orwig reports consulting agreements with Viking Therapeutics, Inc. and Kinexum. Dr. Miller is a full-time employee of the the Novartis Institutes for BioMedical Research, and owns stock in several biomedical companies including Novartis, GlaxoSmithKline, Viking Therapeutics and GTx Incorporated. Dr. Magaziner reports personal fees from Pluristem, Novartis, Viking, Ammonett, Sanofi, and Scholar Rock
From:
J Frailty Aging. 2018;7(3):162-169. doi: 10.14283/jfa.2018.15.
Examining Differences in Recovery Outcomes between Male and Female Hip Fracture Patients: Design and Baseline Results of a Prospective Cohort Study from the Baltimore Hip Studies.
Orwig D1, Hochberg MC, Gruber-Baldini AL, Resnick B, Miller RR, Hicks GE, Cappola AR, Shardell M, Sterling R, Hebel JR, Johnson R, Magaziner J.
Note: another peek at the activity going on that we don't normally get to see. Consultants and collaborators to help advance Pluristem's revolutionary therapeutics. Guess why they hired Dr.Magaziner? (hint: hip fracture)
Interesting! Note the following (I mean the fabulous three):
During the slide between 2000 and 2002, the value of Amazon’s shares went from a high of $106 to a low of just $6.
Think about that! Even worse than PSTI (LOL!). Worked out in the end though!